InoLife Technologies, Inc. Names Michael W. Hunter to Its Board of Directors and Executive Committee

/ Source: GlobeNewswire

RALEIGH, N.C., Feb. 24, 2011 (GLOBE NEWSWIRE) -- InoLife Technologies, Inc. (OTCBB:INOL), an innovative healthcare products development and marketing company has appointed Michael W. Hunter a member of the Board of Directors and a member of the Board's Executive Committee.

Mr. Hunter has more than 25 years of extensive executive management and business development experience. Currently, Mr. Hunter is a Senior Vice President at Carriage Hill Partners where he has a proven track record and respected reputation for facilitating the growth of middle market companies between $50 million and $300 million in challenging markets. He specializes in identifying strategic merger and acquisition targets, capital growth initiatives, and financial restructuring.

Prior to Carriage Hill, Mr. Hunter was President of Development Corporation of Destin (FL) where he identified regional joint ventures, strategic partnerships, structured finance and overall corporate strategy.

"Michael is an exceptional strategic thinker and has a long-standing record of taking organizations to the next level," said Gary Berthold, CEO of InoLife. "Michael's demonstrated ability to build companies and raise capital, along with his understanding of business dynamics and constructive change, are all valuable qualities and we are excited to have him on the team."

"I am privileged to join InoLife's dynamic team and look forward to working with a progressive leader in healthcare products," said Mr. Hunter.

Mr. Hunter graduated summa cum laude from Springfield College.

About InoLife Technologies, Inc.

InoLife is poised to become one of the premier U.S. marketers of state-of-the-art DNA-based test products. Positioned for growth and success in a burgeoning market, InoLife Technologies,, is primarily focused on products, services and solutions that will enable state-of-the-art healthcare for today and the future for a diverse base of customers and end users. The Company's mission is to identify, develop, integrate and bring to market innovative healthcare-based products and services that provide timely and practical solutions. The primary products and services that InoLife is currently addressing focuses upon those specific products and services that provide key solutions through the innovative use of specific DNA testing and Genetic analysis systems.

The principal customers of InoLife's products and services are healthcare providers, physicians, practitioners, hospitals and outpatient facilities. InoLife will be marketing and distributing its products through traditional distribution channels. Additionally, InoLife has developed certain products that can be sold directly to consumers and has created specific programs to reach those customers including e-commerce, direct sales, healthcare providers, pharmacies, distributors, retail sellers and specialty retailers.

Forward-Looking Statements

Safe Harbor Statement under the Private securities Litigation Reform Act of 1995: The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements including, but not limited to, certain delays beyond the Company's control with respect to market acceptance of new technologies, products and services, delays in testing and evaluation of products and services, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

CONTACT: Henry Harrison IR Pro 2.0, Inc. 407-862-5151